Medical Health & Life Science Research News

New report: 20s proteasome pipeline research for 2017

New report: 20s proteasome pipeline research for 2017

20s Proteasome Pipeline and Therapeutics Development H1 2017 provides a comprehensive information on the therapeutics under development for 20s Proteasome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type.

- Advertisement -
- Membership expired -

20s Proteasome Pipeline and Therapeutics Development H1 2017 provides comprehensive information on the therapeutics under development for 20s Proteasome, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

20s Proteasome pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources.

- Advertisement -
- Membership expired -

Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Sample copy is available at www.marketinsightsreports.com/repo…w-h2-2017/inquiry

According to the recently published report '20s Proteasome - Pipeline Review, H2 2017'; 20s Proteasome pipeline Target constitutes close to 7 molecules. Out of which approximately 6 molecules are developed by companies and remaining by the universities/institutes. 

20s Proteasome - 20S proteasome is the catalytic core of the 26S proteasome, the central protease of the ubiquitin pathway of protein degradation. It is commonly associated with regulatory complexes, which include the 19S Proteasome, the PA28 alpha/beta complex, or the PA28 gamma complex.

The 20S Proteasome is composed of 28 subunits arranged into four stacked rings. Unlike the 26S proteasome, which degrades proteins in an ATP-dependent manner, the 20S proteasome is ATP-independent and only degrades entirely unfolded polypeptides. 

The report '20s Proteasome - Pipeline Review, H2 2017' outlays comprehensive information on the 20s Proteasome targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies / Universities.

It also reviews key players involved in 20s Proteasome targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Phase III, Phase II, Preclinical and Discovery stages are 1, 2, 1 and 2 respectively.

Similarly, the universities portfolio in Discovery stages comprises 1 molecules, respectively. Report covers products from therapy areas Oncology, Immunology, Infectious Disease, Metabolic Disorders, Non Malignant Disorders and Women's Health which include indications Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Gynecological Cancer, Multiple Myeloma (Kahler Disease), Waldenstrom Macroglobulinemia, Acute Lymphocytic Leukemia (ALL, Acute Lymphoblastic Leukemia), Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia), Amyloidosis, Breast Cancer, Chronic Lymphocytic Leukemia (CLL), Colon Cancer, Cutaneous T-Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Endometriosis, Glioblastoma Multiforme (GBM), Gliosarcoma, Hematological Tumor, Kidney Transplant Rejection, Lymphoma, Malignant Glioma, Mantle Cell Lymphoma, Metastatic Hormone Refractory (Castration Resistant, Androgen-Independent) Prostate Cancer, Neuroendocrine Cancer, Non-Small Cell Lung Cancer, Ovarian Cancer, Peripheral T-Cell Lymphomas (PTCL), Prostate Cancer, Renal Cell Carcinoma, Skin Cancer, Small-Cell Lung Cancer, Solid Tumor, T-Cell Lymphomas, Tuberculosis and Uterine Leiomyoma (Uterine Fibroids).

Browse full Report at www.marketinsightsreports.com/repo…ne-review-h2-2017

Scope of this report:

  • The pipeline guide provides a snapshot of the global therapeutic landscape of 20s Proteasome. The pipeline guide reviews pipeline therapeutics for 20s Proteasome by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages. The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in 20s Proteasome therapeutics and enlists all their major and minor projects. The pipeline guide evaluates 20s Proteasome therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects. The pipeline guide reviews latest news related to pipeline therapeutics for 20s Proteasome.
  • This research report can: Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies. Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for 20s Proteasome. Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies. Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding 20s Proteasome pipeline depth and focus of Indication therapeutics. Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

News From

Market Insights ReportsMarket Insights Reports
Category: Market Research Publishers and RetailersCompany profile: MarketInsightsReports is your single point market research source for all industries including pharmaceutical, chemicals and materials, energy resource, automobile, IT, technology and media, food and beverages, and consumer goods, among others.  

For more information:

Make an Inquiry about this report HERE!
  • www.marketinsightsreports.com/repo…ne-review-h2-2017
  • www.marketinsightsreports.com/repo…w-h2-2017/inquiry